Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Chiglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CMAP
- Sponsors Chipscreen Biosciences
- 23 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2018.
- 23 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Nov 2017.
- 10 Jun 2017 Biomarkers information updated